News|Articles|July 17, 2024

Pharma Pulse 7/17/24: Pharmacists Report Burnout as Major Driver of Understaffing, Life Sciences Firms Adopt Tools to Modernize Clinical Trials & more

The latest news for pharma industry insiders.

Catalent Finalizes Schorndorf Plant Development Project

The clinical supply facility undergoes a $25 million expansion, welcoming 32,000 more square feet of temperature-controlled storage.

Pharmacists Report Burnout is a Major Driver of Understaffing in Pharmacy Times Survey

Recent findings from a Pharmacy Times survey.

OpenAI Scale Ranks Progress Toward ‘Human-Level’ Problem Solving

The company believes its technology is approaching the second level of five on the path to artificial general intelligence.

Life Sciences Firms Adopt Tools to Modernize Clinical Trials

Technologies that enable decentralized clinical trials and other new practices are transforming the global life sciences industry, according to a new research report published today by Information Services Group.

Avalere Health on LinkedIn

Establishing a whole-person health strategy requires identifying and collaborating with the right stakeholders across the product lifecycle and working with a partner who understands the dynamic market landscape. CEO Jon Koch discusses the challenges and opportunities in achieving whole person health in this article with Pharmaceutical Executive: https://bit.ly/3S3FwHF

#WeAreAvalereHealth #AvalereHealth #MarketAccess #HealthCareMarket

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.